Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inh Galecto Reports Full-Year 2024 ...
Acquired global rights to GB3226, a novel dual ENL-YEATS and FLT3 inhibitor aimed at multiple genetic subsets of acute myeloid leukemia (AML), signaling a strategic focus on oncology. GB3226 is on ...
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback